Zobrazeno 1 - 10
of 201
pro vyhledávání: '"Jörg Timm"'
Autor:
Patrik Roser, Mona Brunstein, Michael Specka, Jörg Timm, Stefan Kühnhold, Fabrizio Schifano, Udo Bonnet, Norbert Scherbaum
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-10 (2024)
Abstract Background Direct acting antivirals (DAAs) as a curative treatment of hepatitis C have been available for several years and have replaced interferon-containing therapies. However, treatment rates of people who inject drugs (PWID) are declini
Externí odkaz:
https://doaj.org/article/9861bcb80e984246810b3ef275bf47ed
Autor:
Alexander Killer, Smaranda Gliga, Carolin Lohr, Christian Weigel, Björn-Erik Ole Jensen, Nadine Lübke, Andreas Walker, Jörg Timm, Johannes Bode, Tom Luedde, Hans H. Bock
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 3, Pp 353-360 (2024)
Background and Aims: The entry inhibitor bulevirtide represents the first specific treatment for hepatitis-D virus (HDV)-infected patients. In clinical trials, around 80% of patients achieve normalization of alanine aminotransferase (ALT) with about
Externí odkaz:
https://doaj.org/article/20cc424499e749c1ab58893002175fbd
Autor:
Carolin Balloff, Carolina Bandlow, Michael Bernhard, Timo Brandenburger, Patricia Bludau, Saskia Elben, Torsten Feldt, Christian J. Hartmann, Elisa Heinen, Jens Ingwersen, Corinna Jansen, Björn-Erik O. Jensen, Detlef Kindgen-Milles, Tom Luedde, Iris-Katharina Penner, Isabel Slink, Kim Stramm, Ann-Kathrin Telke, Jörg Timm, Lana Vetterkind, Christian Vollmer, Georg Wolff, Alfons Schnitzler, Sven G. Meuth, Stefan J. Groiss, Philipp Albrecht
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Neurological manifestations of coronavirus disease 2019 (COVID-19) have been frequently described. In this prospective study of hospitalized COVID-19 patients without a history of neurological conditions, we aimed to analyze their prevalence
Externí odkaz:
https://doaj.org/article/0b0db6727fd14464978c557e6c7fb60a
Autor:
Felix Dewald, Martin Pirkl, Martha Paluschinski, Joachim Kühn, Carina Elsner, Bianca Schulte, Jacqueline Knüfer, Elvin Ahmadov, Maike Schlotz, Göksu Oral, Michael Bernhard, Mark Michael, Maura Luxenburger, Marcel Andrée, Marc Tim Hennies, Wali Hafezi, Marlin Maybrit Müller, Philipp Kümpers, Joachim Risse, Clemens Kill, Randi Katrin Manegold, Ute von Frantzki, Enrico Richter, Dorian Emmert, Werner O. Monzon-Posadas, Ingo Gräff, Monika Kogej, Antonia Büning, Maximilian Baum, Finn Teipel, Babak Mochtarzadeh, Martin Wolff, Henning Gruell, Veronica Di Cristanziano, Volker Burst, Hendrik Streeck, Ulf Dittmer, Stephan Ludwig, Jörg Timm, Florian Klein
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Determining SARS-CoV-2 immunity is critical to assess COVID-19 risk and the need for prevention and mitigation strategies. We measured SARS-CoV-2 Spike/Nucleocapsid seroprevalence and serum neutralizing activity against Wu01, BA.4/5 and BQ.1
Externí odkaz:
https://doaj.org/article/7e717247ee2347da9986fd97ed699afb
Autor:
Battur Magvan, Anne Alina Kloeble, Johannes Ptok, Daniel Hoffmann, Daniel Habermann, Anuujin Gantumur, Martha Paluschinski, Gerelmaa Enebish, Vera Balz, Johannes C. Fischer, Battogtokh Chimeddorj, Andreas Walker, Jörg Timm
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionThe Hepatitis Delta Virus (HDV) is a defective, single-stranded RNA virusoid encoding for a single protein, the Hepatitis Delta Antigen (HDAg), which requires the hepatitis B virus (HBV) envelope protein (HBsAg) for its transmission. Curr
Externí odkaz:
https://doaj.org/article/d8369fd098da4b92ad5f636f417decf5
Autor:
Benjamin Krämer, Ansel P. Nalin, Feiyang Ma, Sarah Eickhoff, Philipp Lutz, Sonia Leonardelli, Felix Goeser, Claudia Finnemann, Gudrun Hack, Jan Raabe, Michael ToVinh, Sarah Ahmad, Christoph Hoffmeister, Kim M. Kaiser, Steffen Manekeller, Vittorio Branchi, Tobias Bald, Michael Hölzel, Robert Hüneburg, Hans Dieter Nischalke, Alexander Semaan, Bettina Langhans, Dominik J. Kaczmarek, Brooke Benner, Matthew R. Lordo, Jesse Kowalski, Adam Gerhardt, Jörg Timm, Marieta Toma, Raphael Mohr, Andreas Türler, Arthur Charpentier, Tobias van Bremen, Georg Feldmann, Arne Sattler, Katja Kotsch, Ali T. Abdallah, Christian P. Strassburg, Ulrich Spengler, William E. Carson, III, Bethany L. Mundy-Bosse, Matteo Pellegrini, Timothy E. O’Sullivan, Aharon G. Freud, Jacob Nattermann
Publikováno v:
Cell Reports, Vol 42, Iss 1, Pp 111937- (2023)
Summary: Group 1 innate lymphoid cells (ILCs) comprise a heterogeneous family of cytotoxic natural killer (NK) cells and ILC1s. We identify a population of “liver-type” ILC1s with transcriptional, phenotypic, and functional features distinct from
Externí odkaz:
https://doaj.org/article/0084e5451ed64fc0b420c8bfd7ffa888
Autor:
Andreas Walker, Tatjana Schwarz, Janine Brinkmann-Paulukat, Karin Wisskirchen, Christopher Menne, Elahe Salimi Alizei, Helenie Kefalakes, Martin Theissen, Daniel Hoffmann, Julian Schulze zur Wiesch, Mala K. Maini, Markus Cornberg, Anke RM Kraft, Verena Keitel, Hans H. Bock, Peter A. Horn, Robert Thimme, Heiner Wedemeyer, Falko M. Heinemann, Tom Luedde, Christoph Neumann-Haefelin, Ulrike Protzer, Jörg Timm
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Background and aimsThere is growing interest in T cell-based immune therapies for a functional cure of chronic HBV infection including check-point inhibition, T cell-targeted vaccines or TCR-grafted effector cells. All these approaches depend on reco
Externí odkaz:
https://doaj.org/article/a835df343e524209b827b09b26d8af46
Autor:
Lisa Müller, Marcel Andrée, Wiebke Moskorz, Ingo Drexler, Sandra Hauka, Johannes Ptok, Lara Walotka, Ramona Grothmann, Jonas Hillebrandt, Anastasia Ritchie, Laura Peter, Andreas Walker, Jörg Timm, Ortwin Adams, Heiner Schaal
Publikováno v:
Frontiers in Aging, Vol 3 (2022)
We provide follow-up data on the humoral immune response after COVID-19 vaccinations of two distinct cohorts aged below 60 and over 80 years to screen for age-related differences in the longevity and magnitude of the induction of the antibody respons
Externí odkaz:
https://doaj.org/article/22f687e3b17c44a8a83efd4129099116
Autor:
Verena Keitel, Björn Jensen, Torsten Feldt, Johannes C. Fischer, Johannes G. Bode, Christiane Matuschek, Edwin Bölke, Wilfried Budach, Christian Plettenberg, Kathrin Scheckenbach, Detlef Kindgen-Milles, Jörg Timm, Lisa Müller, Henrike Kolbe, Andreas Stöhr, Christian Calles, Andreas Hippe, Pablo Verde, Christoph D. Spinner, Jochen Schneider, Timo Wolf, Winfried V. Kern, Jacob Nattermann, Alexander Zoufaly, Christian Ohmann, Tom Luedde, RES-Q-HR Trial Team
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Abstract Objectives Currently, there are no approved treatments for early disease stages of COVID-19 and few strategies to prevent disease progression after infection with SARS-CoV-2. The objective of this study is to evaluate the safety and efficacy
Externí odkaz:
https://doaj.org/article/8d3cbe2e18e847ccaceadebaea8ebecd
Autor:
Tina Senff, Christopher Menne, Christine Cosmovici, Lia Laura Lewis-Ximenez, Jasneet Aneja, Ruth Broering, Arthur Y. Kim, Astrid M. Westendorf, Ulf Dittmer, Norbert Scherbaum, Georg M. Lauer, Jörg Timm
Publikováno v:
JCI Insight, Vol 7, Iss 2 (2022)
Invariant NK T (iNKT) cells are implicated in viral clearance; however, their role in hepatitis C virus (HCV) infection remains controversial. Here, iNKT cells were studied during different stages of HCV infection. iNKT cells from patients with acute
Externí odkaz:
https://doaj.org/article/d2ce0e1d8a7643998475de34972c062b